ArticleFrontiers in medicine2025
Evaluation of the zinc-fingers and homeoboxes 3 as a potential biomarker for prognosis prediction in lung adenocarcinoma.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is one of the leading malignant cancers in the world with high incidence and mortality and lung adenocarcinoma (LUAD) is its major histologic subtype. Molecular biomarkers that hold prognostic value and therapeutic implication are required to evaluate disease development and enhance the survival outcomes of cancer patients. Materials and methods: The current study performed bioinformatics analysis via various online datasets and immunohistochemistry to examine the expression status of the zinc-fingers and homeoboxes (ZHX) family members as well as their prognostic implications in lung cancer as well as in its subtypes. Results: We observed that high mRNA levels of ZHX factors indicated favorable overall survival in patients with lung cancer. Subgroup analysis demonstrated notable associations between the expression levels of ZHX family members and survival outcomes in select patient cohorts. Immunohistochemistry confirmed that low ZHX3 protein expression had stronger correlation with malignant properties and unfavorable OS in LUAD patients. Multivariate analysis revealed that ZHX3 expression was as an independent predictor for prognosis. Conclusion: Thus, we supposed that ZHX3 might be a potential survival biomarker in outcome prediction for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.